Abstract Triple-negative breast cancer (TNBC) exhibits the poorest outcomes among breast cancer subtypes due to the high heterogeneity and a lasting scarcity of effectual treatments. Targeted therapies based on molecular subtypes of TNBC are critical step toward tailoring treatments to improve clinical outcomes. Gastrointestinal cancer stem cell (CSC) marker DCLK1 was reported to be h... https://prhxynuqry7b7c.wikimidpoint.com/5250089/a_systematic_review_of_the_interrelations_of_urban_form_and_mode_choice_in_african_cities